EVE Energy Launches New CR123AP Medical Battery

2026-04-19 | Calvin

On April 9th, the 93rd China International Medical Equipment (Spring) Expo officially opened. EVE Energy made a striking debut with its new CR123AP medical battery, safeguarding life and health with cutting-edge technology and promoting a better life through green manufacturing principles.

With over twenty years of dedication to the medical field, EVE Energy has always adhered to the core philosophy that "a battery is a living entity, and we approach each one with respect to ensure its quality." The company has established a comprehensive medical battery product system covering implantable medical devices, in vitro diagnostics, emergency equipment, and more. Currently, as AEDs (automated external defibrillators) penetrate more scenarios and devices such as electric staplers continue to upgrade, the industry demands higher reliability and adaptability from supporting batteries. EVE Energy, with keen insight into these challenges, has launched the CR123AP medical battery, an innovative solution designed to address industry pain points and meet market upgrading needs.

CR123AP: Setting a New Benchmark in Medical Batteries

The CR123AP, an advanced product for the medical field, tackles key challenges of traditional medical batteries, such as poor adaptability to extreme environments and delayed pulse energy, with four core advantages:

• Ultra-long cycle life: Featuring high-pulse output technology, the CR123AP far exceeds the industry average in cycle count, significantly enhancing the long-term efficiency of medical devices.
• Excellent rate performance: Provides a stable, high-rate pulse platform for precise and reliable activation, meeting the stringent operational requirements of medical equipment.
• Extreme low-temperature performance: Maintains pulse output capability up to 5.92 times that of competitors at -20℃, overcoming limitations in low-temperature environments.
• Green and eco-friendly design: Manufactured using a dry-process technique that ensures a low-carbon footprint throughout production, balancing performance with sustainability.

The CR123AP’s performance breakthroughs are driven by EVE Energy’s innovative dry electrode technology. Unlike traditional solvent-based slurry methods, this technology eliminates harmful solvents, simplifies production processes, reduces carbon emissions, and significantly enhances the electrode’s electrical conductivity and mechanical stability. As a result, the battery achieves comprehensive improvements in pulse output strength, low-temperature adaptability, and long-term operational reliability, fully meeting the rigorous standards of medical devices.

Through continuous technological iteration, EVE Energy keeps pushing performance boundaries: optimizing self-discharge characteristics to extend effective lifespan, expanding temperature adaptability, and ensuring high consistency and safety through AI-powered quality inspection and digital manufacturing.

From project initiation in 2025 to mass production in 2026, the CR123AP medical battery will be manufactured simultaneously at EVE Energy’s dual production bases in Jingmen, China, and Penang, Malaysia. This global capacity layout empowers medical customers worldwide and supports the iterative upgrading of medical devices. With unwavering dedication and continuous innovation, EVE Energy will keep focusing on market demands and technological breakthroughs, advancing the medical battery field, safeguarding life and health, and enabling a better life through green manufacturing.